Medicina
Departamento
Karmanos Cancer Institute
Detroit, Estados UnidosPublicacións en colaboración con investigadores/as de Karmanos Cancer Institute (8)
2023
-
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 2007-2019
2022
-
Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer
New England Journal of Medicine, Vol. 386, Núm. 3, pp. 241-251
2020
-
Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial
Bladder Cancer, Vol. 6, Núm. 1, pp. 43-52
-
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 1, pp. 105-120
2018
-
Phase I study of CC-486 alone and in combination with carboplatin or nab-paclitaxel in patients with relapsed or refractory solid tumors
Clinical Cancer Research, Vol. 24, Núm. 17, pp. 4072-4080
2017
-
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies
Clinical Lung Cancer, Vol. 18, Núm. 5, pp. 489-496
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2013
-
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement
Cancer Discovery, Vol. 3, Núm. 4, pp. 406-417